Published On: Mon, Mar 20th, 2017

This Weeks Target Prices For Zosano Pharma Corporation (ZSAN)

Recently stock market analysts have updated their consensus ratings on shares of Zosano Pharma Corporation (ZSAN).

Most recent broker ratings

02/15/2017 – Zosano Pharma Corporation had its “buy” rating reiterated by analysts at Roth Capital. They now have a USD 3.25 price target on the stock.

08/11/2016 – Zosano Pharma Corporation was downgraded to “neutral” by analysts at Ladenburg Thalmann.

05/14/2015 – Zosano Pharma Corporation was downgraded to “hold” by analysts at Zacks.

Zosano Pharma Corporation has a 50 day moving average of 2.02 and a 200 day moving average of 1.10. The stock’s market capitalization is 32.68M, it has a 52-week low of 0.45 and a 52-week high of 3.54.

The share price of the company (ZSAN) was up +8.39% during the last trading session, with a high of 1.74 and the volume of Zosano Pharma Corporation shares traded was 3885823.

Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability. The Company’s short-wear-time transdermal patch consists of an array of titanium microneedles that is coated with its formulation of an approved drug and attached to an adhesive patch. When the patch is applied with its hand-held applicator, the microneedles painlessly penetrate the skin, resulting in rapid dissolution and absorption of the drug coating through the capillary bed. Its product candidates include ZP-Triptan, ZP-Glucagon and ZP-PTH. ZP-PTH is a formulation of teriparatide, a synthetic form of parathyroid hormone. ZP-Glucagon is a formulation of glucagon.